亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Patient-reported outcomes following pembrolizumab or placebo plus pemetrexed and platinum in patients with previously untreated, metastatic, non-squamous non-small-cell lung cancer (KEYNOTE-189): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial

医学 培美曲塞 卡铂 肺癌 内科学 实体瘤疗效评价标准 安慰剂 肿瘤科 彭布罗利珠单抗 癌症 化疗 外科 进行性疾病 顺铂 病理 免疫疗法 替代医学
作者
Marina Chiara Garassino,Shirish M. Gadgeel,Emilio Esteban,Enriqueta Felip,Giovanna Speranza,Manuel Dómine,Maximilian J. Hochmair,Steven Powell,Susanna Y. Cheng,Helge Bischoff,Nir Peled,Martin Reck,Rina Hui,Edward B. Garon,Michael Boyer,Ziwen Wei,Thomas Burke,M. Catherine Pietanza,Delvys Rodríguez‐Abreu
出处
期刊:Lancet Oncology [Elsevier BV]
卷期号:21 (3): 387-397 被引量:210
标识
DOI:10.1016/s1470-2045(19)30801-0
摘要

Background Pembrolizumab plus pemetrexed–platinum led to superior overall survival and progression-free survival, and a higher proportion of patients with a confirmed complete or partial response over placebo plus pemetrexed–platinum in the KEYNOTE-189 study. We aimed to evaluate prespecified exploratory patient-reported outcomes (PROs) in patients in KEYNOTE-189. Methods In the multicentre, double-blind, randomised, placebo-controlled, phase 3 KEYNOTE-189 study done at 126 cancer centres in 16 countries, eligible patients aged 18 years or older with histologically or cytologically confirmed metastatic non-squamous non-small-cell lung cancer without sensitising EGFR or ALK alterations, measurable disease as per Response Evaluation Criteria in Solid Tumors (version 1.1), and an Eastern Cooperative Oncology Group performance status of 0 or 1 were enrolled. Patients were randomly assigned (2:1) to receive intravenous pembrolizumab (200 mg) or saline placebo every 3 weeks for up to 2 years (35 cycles); all patients received four cycles of intravenous pemetrexed (500 mg/m2) with carboplatin (5 mg/mL per min) or cisplatin (75 mg/m2; investigator's choice) every 3 weeks for four cycles, followed by pemetrexed maintenance therapy every 3 weeks. Permuted block randomisation (block size six) was done with an interactive voice-response system and stratified by PD-L1 expression, choice of platinum, and smoking status. Patients, investigators, and other study personnel were unaware of treatment assignment. The European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire-Core 30 (QLQ-C30) and Lung Cancer 13 (QLQ-LC13) were administered at cycles 1–5, every three cycles thereafter during year 1, and every four cycles during years 2–3. The primary endpoints (overall survival and progression-free survival) have been published previously. Key PRO endpoints were change from baseline to week 12 (during chemotherapy) and week 21 (following chemotherapy) in QLQ-C30 global health status/quality of life (GHS/QOL) score, and time to deterioration in cough, chest pain, or dyspnoea. PROs were analysed in all randomly assigned patients who received at least one dose of study medication and who completed at least one PRO assessment, and the results are provided with two-sided, nominal p values. This ongoing study is registered with ClinicalTrials.gov, number NCT02578680. Findings Between Feb 26, 2016, and March 6, 2017, 616 patients were enrolled; median follow-up was 10·5 months (range 0·2–20·4) as of data cutoff on Nov 8, 2017. 402 (99%) of 405 patients in the pembrolizumab plus pemetrexed–platinum group and 200 (99%) of 202 patients in the placebo plus pemetrexed–platinum-treated group completed at least one PRO assessment. At baseline, 359 (89%) of 402 patients in the pembrolizumab plus pemetrexed–platinum group and 180 (90%) of 200 in the placebo plus pemetrexed–platinum group were compliant with QLQ-C30; at week 12, 319 (90%) of 354 and 149 (89%) of 167 patients were compliant, respectively; and at week 21, 249 (76%) of 326 and 91 (64%) of 143 patients were compliant, respectively. From baseline to week 12, GHS/QOL scores were maintained with both pembrolizumab plus pemetrexed–platinum (least-squares mean change: 1·0 point [95% CI −1·3 to 3·2] increase) and placebo plus pemetrexed–platinum (−2·6 points [−5·8 to 0·5] decrease; between-group difference: 3·6 points [−0·1 to 7·2]; p=0·053). From baseline to week 21, GHS/QOL scores were better maintained with pembrolizumab plus pemetrexed–platinum (least-squares mean change: 1·3 points [95% CI −1·2 to 3·6] increase) than with placebo plus pemetrexed–platinum (−4·0 points [−7·7 to −0·3] decrease; between-group difference: 5·3 points [1·1 to 9·5]; p=0·014). Median time to deterioration in cough, chest pain, or dyspnoea was not reached (95% CI 10·2 months to not reached) with pembrolizumab plus pemetrexed–platinum, and was 7·0 months (4·8 months to not reached) with placebo plus pemetrexed–platinum (hazard ratio 0·81 [95% CI 0·60–1·09], p=0·16). Interpretation The addition of pembrolizumab to standard chemotherapy maintained GHS/QOL, with improved GHS/QOL scores at week 21 in the pembrolizumab plus chemotherapy group compared with the placebo plus chemotherapy group. These data further support use of pembrolizumab plus pemetrexed–platinum as first-line therapy for patients with metastatic non-squamous non-small-cell lung cancer. Funding Merck Sharp & Dohme.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
5秒前
5秒前
vfdhjng发布了新的文献求助10
5秒前
完美世界的应助被撩寮采纳,获得10
8秒前
康子浩发布了新的文献求助10
11秒前
多情嫣然完成签到,获得积分10
15秒前
16秒前
ZaZa完成签到,获得积分10
16秒前
19秒前
summerer发布了新的文献求助10
25秒前
Lucas的应助被科研通管家采纳,获得10
26秒前
852的应助被科研通管家采纳,获得10
27秒前
共享精神的应助被科研通管家采纳,获得10
27秒前
殷宵箫发布了新的文献求助10
27秒前
英姑的应助被科研通管家采纳,获得10
27秒前
含蓄的芝麻完成签到,获得积分10
29秒前
ADAB0002完成签到,获得积分10
30秒前
果冻完成签到 ,获得积分10
31秒前
31秒前
vfdhjng完成签到,获得积分20
33秒前
33秒前
可爱的函函的应助被lx采纳,获得10
35秒前
36秒前
华仔的应助被怡宝采纳,获得10
37秒前
summerer发布了新的文献求助20
38秒前
39秒前
嘻嘻哈哈的应助被Gloria采纳,获得10
39秒前
费洛蒙漩涡完成签到,获得积分10
40秒前
孤独孤风完成签到,获得积分10
40秒前
苹果颖完成签到,获得积分10
41秒前
lx完成签到,获得积分10
42秒前
43秒前
43秒前
科研通AI6.4的应助被殷宵箫采纳,获得10
43秒前
44秒前
鱼鱼鱼完成签到,获得积分10
46秒前
lx发布了新的文献求助10
48秒前
48秒前
顺心尔冬完成签到,获得积分10
48秒前
49秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Hidden Empire of Finance: How Wall Street Profits from Our Cities and Fuels Global Inequality 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8165846
求助须知:如何正确求助?哪些是违规求助? 9559318
关于积分的说明 21749858
捐赠科研通 7756681
什么是DOI,文献DOI怎么找? 3429083
关于科研通互助平台的介绍 2553354
邀请新用户注册赠送积分活动 2473622